- Home
- EDSA vs ULY Comparison
EDSA vs ULY Comparison
Compare EDSA & ULY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- ULY
- Stock Information
- Founded
- EDSA 2015
- ULY 2013
- Country
- EDSA Canada
- ULY United States
- Employees
- EDSA N/A
- ULY N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- ULY
- Sector
- EDSA Health Care
- ULY
- Exchange
- EDSA Nasdaq
- ULY Nasdaq
- Market Cap
- EDSA 13.7M
- ULY 14.8M
- IPO Year
- EDSA N/A
- ULY N/A
- Fundamental
- Price
- EDSA $4.28
- ULY $0.65
- Analyst Decision
- EDSA Strong Buy
- ULY Strong Buy
- Analyst Count
- EDSA 2
- ULY 1
- Target Price
- EDSA $39.00
- ULY $2.00
- AVG Volume (30 Days)
- EDSA 8.9K
- ULY 590.1K
- Earning Date
- EDSA 08-09-2024
- ULY 11-12-2024
- Dividend Yield
- EDSA N/A
- ULY N/A
- EPS Growth
- EDSA N/A
- ULY N/A
- EPS
- EDSA N/A
- ULY 7.76
- Revenue
- EDSA N/A
- ULY $165,727,000.00
- Revenue This Year
- EDSA N/A
- ULY N/A
- Revenue Next Year
- EDSA N/A
- ULY $20.40
- P/E Ratio
- EDSA N/A
- ULY $0.08
- Revenue Growth
- EDSA N/A
- ULY N/A
- 52 Week Low
- EDSA $2.46
- ULY $0.64
- 52 Week High
- EDSA $8.33
- ULY $12.00
- Technical
- Relative Strength Index (RSI)
- EDSA 45.00
- ULY 27.44
- Support Level
- EDSA $4.20
- ULY $0.65
- Resistance Level
- EDSA $5.00
- ULY $0.72
- Average True Range (ATR)
- EDSA 0.23
- ULY 0.08
- MACD
- EDSA 0.01
- ULY -0.00
- Stochastic Oscillator
- EDSA 14.29
- ULY 2.89
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.
About ULY Urgent.ly Inc.
Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and lead to long wait times. Urgently offers an innovative alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.